SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on December 31, 2019. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Westport, Connecticut. The report discloses the entry into a material definitive agreement regarding a private placement of common stock.
Key Financial Metrics
The filing details a specific capital raise transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Shares Issued: 231,335 shares of common stock.
- Purchase Price: $6.00 per share.
- Gross Proceeds: Approximately $1.39 million.
- Net Proceeds: Approximately $1.38 million (after estimated offering expenses).
- Use of Proceeds: Working capital and general corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, debt levels, or liquidity ratios outside of the transaction proceeds.
Material Changes
The primary material change reported is the increase in equity capital and cash assets resulting from the closing of the Securities Purchase Agreement on December 31, 2019. This transaction was conducted pursuant to an effective shelf registration statement (Form S-3) filed in March 2019.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds for working capital and general corporate purposes. The filing includes standard risk disclosures regarding the Purchase Agreement, noting that representations and warranties are for the benefit of the parties to the agreement and should not be relied upon as statements of fact by stockholders. The document does not provide specific forward-looking guidance on future revenue or earnings.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $1.38 million.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Confirm the impact of the 231,335 new shares on total outstanding share count and potential dilution.
- Check subsequent filings for updates on how the working capital proceeds were utilized.